- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Patent holdings for IPC class C07D 403/12
Total number of patents in this class: 9786
10-year publication summary
|
696
|
640
|
666
|
641
|
730
|
722
|
676
|
760
|
599
|
316
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4898 |
211 |
| Boehringer Ingelheim International GmbH | 4650 |
160 |
| F. Hoffmann-La Roche AG | 7925 |
149 |
| Novartis AG | 10849 |
129 |
| Janssen Pharmaceutica N.V. | 3392 |
119 |
| Vertex Pharmaceuticals Incorporated | 1597 |
104 |
| AstraZeneca AB | 2909 |
101 |
| BASF SE | 20933 |
100 |
| Hoffmann-La Roche Inc. | 3418 |
90 |
| Merck Patent GmbH | 5831 |
88 |
| Merck Sharp & Dohme LLC | 3748 |
87 |
| Genentech, Inc. | 3976 |
84 |
| Pfizer Inc. | 3387 |
83 |
| Takeda Pharmaceutical Company Limited | 2713 |
75 |
| Gilead Sciences, Inc. | 2036 |
68 |
| Amgen Inc. | 4074 |
63 |
| Dana-Farber Cancer Institute, Inc. | 2571 |
61 |
| Bayer AG | 3330 |
58 |
| Array BioPharma Inc. | 502 |
57 |
| The Regents of the University of California | 19918 |
55 |
| Other owners | 7844 |